| http://www.w3.org/ns/prov#value | - Overall, Novartis presented 14 abstracts, including data from the investigational QVA149 (fixed-dose combination of indacaterol maleate/glycopyrronium bromide) IGNITE Phase III clinical trial programme, NVA237 (glycopyrronium bromide) ??? an investigational long acting muscarinic antagonist (LAMA) ??? GLOW Phase III clinical trial programme and the indacaterol maleate (Onbrez?? Breezhaler??) ???
|
